Baseline characteristics
Variable . | All patients (N = 478) . | PP (n = 217) . | PR/SD (n = 86) . | ER (n = 175) . |
|---|---|---|---|---|
| Median age at diagnosis (range), y | 31 (15-69) | 32 (15-69) | 29 (17-67) | 30.7 (16-67) |
| Median age at auto-HCT (range), y | 32 (16-71) | 33 (16-71) | 31 (18-68) | 32 (17-69) |
| Age >45 y, n (%) | 76 (16) | 37 (17) | 9 (11) | 30 (17) |
| Sex, n (%) | ||||
| Males | 260 (54) | 122 (56) | 41 (48) | 97 (55) |
| Females | 218 (46) | 95 (44) | 45 (52) | 78 (45) |
| Era of diagnosis, n (%) | ||||
| Era 1 (<2011) | 188 (39) | 70 (32) | 39 (45) | 79 (45) |
| Era 2 (≥2011) | 290 (61) | 147 (67) | 47 (55) | 96 (55) |
| cHL subtype, n (%) | n = 454 | n = 207 | n = 78 | n = 169 |
| NS | 402 (89) | 176 (85.0) | 68 (87) | 158 (93) |
| MC | 42 (9) | 24 (12) | 8 (10) | 10 (6) |
| LR | 3 (1) | 1 (<1) | 1 (1) | 1 (1) |
| LD | 7 (1) | 6 (3) | 1 (1) | 0 (0) |
| ECOG PS at diagnosis, n (%) | n = 279 | n = 129 | n = 53 | n = 97 |
| 0 | 137 (49) | 56 (43) | 30 (57) | 51 (53) |
| 1 | 116 (42) | 59 (46) | 21 (40) | 36 (37) |
| ≥2 | 26 (9) | 14 (11) | 2 (4) | 10 (10) |
| Stage at diagnosis, n (%) | n = 476 | n = 216 | n = 86 | n = 174 |
| 1-2 | 185 (39) | 78 (36) | 37 (43) | 70 (40) |
| 3-4 | 291 (61) | 138 (64) | 49 (57) | 104 (60) |
| B symptoms at diagnosis, n (%) | n = 470 | n = 211 | n = 85 | n = 174 |
| No | 169 (36) | 63 (30) | 30 (35) | 76 (44) |
| Yes | 301 (64) | 148 (70) | 55 (65) | 98 (56) |
| Extranodal involvement at diagnosis, n (%) | n = 345 | n = 164 | n = 54 | n = 127 |
| No | 183 (53) | 80 (49) | 26 (48) | 77 (61) |
| Yes | 162 (47) | 84 (51) | 28 (52) | 50 (39) |
| Subdiaphragmatic presentation at diagnosis, n (%) | n = 471 | n = 215 | n = 84 | n = 172 |
| No | 229 (496) | 95 (44) | 47 (56) | 87 (51) |
| Yes | 242 (51) | 120 (56) | 37 (44) | 85 (49) |
| Bulky disease at diagnosis, n (%) | n = 468 | n = 212 | n = 84 | n = 172 |
| No | 336 (72) | 146 (69) | 54 (64) | 136 (79) |
| Yes | 132 (28) | 66 (31) | 30 (36) | 36 (21) |
| First-line treatment, n (%) | ||||
| ABVD∗ | 451 (94) | 207 (95) | 82 (95) | 162 (93) |
| ABVD/BEACOPP | 4 (1) | 2 (1) | 1 (1) | 1 (1) |
| Stanford V | 4 (1) | 0 (0) | 0 (0) | 4 (2) |
| ABVE-PC | 5 (1) | 2 (1) | 0 (0) | 3 (2) |
| Others | 14 (3) | 6 (3) | 3 (4) | 5 (3) |
| Median lines of treatment before auto-HCT (range) | 2 (1-3) | 2 (1-3) | 2 (1-3) | 2 (1-3) |
| Disease status at auto-HCT, n (%) | n = 464 | n = 208 | n = 84 | n = 172 |
| CR | 251 (54) | 102 (49) | 36 (43) | 113 (66) |
| PR | 176 (38) | 82 (39) | 41 (49) | 53 (31) |
| SD | 21 (5) | 15 (7) | 4 (5) | 2 (1) |
| PD | 16 (3) | 9 (4) | 3 (4) | 4 (2) |
| Conditioning regimen, n (%) | n = 472 | n = 212 | n = 86 | n = 174 |
| BEAM | 330 (70) | 159 (75) | 52 (61) | 119 (68) |
| CBV | 70 (15) | 27 (13) | 20 (23) | 23 (13) |
| Others | 72 (15) | 26 (12) | 14 (16) | 32 (18) |
| Median follow-up (range), mo | 34.5 (0.2-158.5) | 33.4 (0.2-158.5) | 32.9 (0.5-140.6) | 35.3 (0.5-144.5) |
Variable . | All patients (N = 478) . | PP (n = 217) . | PR/SD (n = 86) . | ER (n = 175) . |
|---|---|---|---|---|
| Median age at diagnosis (range), y | 31 (15-69) | 32 (15-69) | 29 (17-67) | 30.7 (16-67) |
| Median age at auto-HCT (range), y | 32 (16-71) | 33 (16-71) | 31 (18-68) | 32 (17-69) |
| Age >45 y, n (%) | 76 (16) | 37 (17) | 9 (11) | 30 (17) |
| Sex, n (%) | ||||
| Males | 260 (54) | 122 (56) | 41 (48) | 97 (55) |
| Females | 218 (46) | 95 (44) | 45 (52) | 78 (45) |
| Era of diagnosis, n (%) | ||||
| Era 1 (<2011) | 188 (39) | 70 (32) | 39 (45) | 79 (45) |
| Era 2 (≥2011) | 290 (61) | 147 (67) | 47 (55) | 96 (55) |
| cHL subtype, n (%) | n = 454 | n = 207 | n = 78 | n = 169 |
| NS | 402 (89) | 176 (85.0) | 68 (87) | 158 (93) |
| MC | 42 (9) | 24 (12) | 8 (10) | 10 (6) |
| LR | 3 (1) | 1 (<1) | 1 (1) | 1 (1) |
| LD | 7 (1) | 6 (3) | 1 (1) | 0 (0) |
| ECOG PS at diagnosis, n (%) | n = 279 | n = 129 | n = 53 | n = 97 |
| 0 | 137 (49) | 56 (43) | 30 (57) | 51 (53) |
| 1 | 116 (42) | 59 (46) | 21 (40) | 36 (37) |
| ≥2 | 26 (9) | 14 (11) | 2 (4) | 10 (10) |
| Stage at diagnosis, n (%) | n = 476 | n = 216 | n = 86 | n = 174 |
| 1-2 | 185 (39) | 78 (36) | 37 (43) | 70 (40) |
| 3-4 | 291 (61) | 138 (64) | 49 (57) | 104 (60) |
| B symptoms at diagnosis, n (%) | n = 470 | n = 211 | n = 85 | n = 174 |
| No | 169 (36) | 63 (30) | 30 (35) | 76 (44) |
| Yes | 301 (64) | 148 (70) | 55 (65) | 98 (56) |
| Extranodal involvement at diagnosis, n (%) | n = 345 | n = 164 | n = 54 | n = 127 |
| No | 183 (53) | 80 (49) | 26 (48) | 77 (61) |
| Yes | 162 (47) | 84 (51) | 28 (52) | 50 (39) |
| Subdiaphragmatic presentation at diagnosis, n (%) | n = 471 | n = 215 | n = 84 | n = 172 |
| No | 229 (496) | 95 (44) | 47 (56) | 87 (51) |
| Yes | 242 (51) | 120 (56) | 37 (44) | 85 (49) |
| Bulky disease at diagnosis, n (%) | n = 468 | n = 212 | n = 84 | n = 172 |
| No | 336 (72) | 146 (69) | 54 (64) | 136 (79) |
| Yes | 132 (28) | 66 (31) | 30 (36) | 36 (21) |
| First-line treatment, n (%) | ||||
| ABVD∗ | 451 (94) | 207 (95) | 82 (95) | 162 (93) |
| ABVD/BEACOPP | 4 (1) | 2 (1) | 1 (1) | 1 (1) |
| Stanford V | 4 (1) | 0 (0) | 0 (0) | 4 (2) |
| ABVE-PC | 5 (1) | 2 (1) | 0 (0) | 3 (2) |
| Others | 14 (3) | 6 (3) | 3 (4) | 5 (3) |
| Median lines of treatment before auto-HCT (range) | 2 (1-3) | 2 (1-3) | 2 (1-3) | 2 (1-3) |
| Disease status at auto-HCT, n (%) | n = 464 | n = 208 | n = 84 | n = 172 |
| CR | 251 (54) | 102 (49) | 36 (43) | 113 (66) |
| PR | 176 (38) | 82 (39) | 41 (49) | 53 (31) |
| SD | 21 (5) | 15 (7) | 4 (5) | 2 (1) |
| PD | 16 (3) | 9 (4) | 3 (4) | 4 (2) |
| Conditioning regimen, n (%) | n = 472 | n = 212 | n = 86 | n = 174 |
| BEAM | 330 (70) | 159 (75) | 52 (61) | 119 (68) |
| CBV | 70 (15) | 27 (13) | 20 (23) | 23 (13) |
| Others | 72 (15) | 26 (12) | 14 (16) | 32 (18) |
| Median follow-up (range), mo | 34.5 (0.2-158.5) | 33.4 (0.2-158.5) | 32.9 (0.5-140.6) | 35.3 (0.5-144.5) |
ABVE-PC, adriamycin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone; BEAM, carmustine, etoposide, cytarabine, and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; ECOG, Eastern Cooperative Oncology Group; LR, lymphocyte rich; LD, lymphocyte depleted; MC, mixed cellularity; NS, nodular sclerosis; PS, performance status.
Includes ABVD/AVD cases as well.